Archives for April 17, 2023

← 2023
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

By Rachel Arthur

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.

Merck to acquire Prometheus Biosciences for $10.8bn

Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.